Ginkgo Bioworks is an American biotech company founded in 2009 by scientists from MIT and headed by Jason Kelly.
| FactSnippet No. 1,566,056 |
10 Facts About Ginkgo Bioworks
2.
Ginkgo Bioworks specializes in using genetic engineering to produce bacteria with industrial applications.
| FactSnippet No. 1,566,057 |
3.
Ginkgo Bioworks is an analytics company that designs microorganisms for customers in a range of industries.
| FactSnippet No. 1,566,058 |
4.
On 16 December 2020, it was reported that Ginkgo Bioworks would acquire the primary assets of Novogy's Microbial Engineering Platform.
| FactSnippet No. 1,566,059 |
5.
On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.
| FactSnippet No. 1,566,060 |
6.
On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform.
| FactSnippet No. 1,566,061 |
7.
On 6 June 2022, it was reported that Ginkgo Bioworks has acquired assets from Bitome, an Integrated Metabolite Monitoring Platform.
| FactSnippet No. 1,566,062 |
8.
On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal.
| FactSnippet No. 1,566,063 |
9.
On 4 October 2022, it was reported that Ginkgo Bioworks would acquire Adaptive Laboratory Evolution Company Altar.
| FactSnippet No. 1,566,064 |
10.
On 4 October 2022, it was reported that Ginkgo Bioworks would acquire Circularis to Strengthen Capabilities in Cell and Gene Therapy.
| FactSnippet No. 1,566,065 |